Important pharmacy news and late-breaking industry information updated daily.
FDA announced Monday that it has approved nine applications for the generic versions of pregabalin (Lyrica—Pfizer) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients aged 17 years a
Cities, towns, and counties on Friday filed thousands of documents from corporations across the pharmaceutical supply chain as they laid out a detailed case of how diverse interests fed an opioid epidemic that persisted for nearly 2 decades.
The American Medical Association (AMA) is asking state and federal authorities to step in to help eliminate the current barriers that prevent so many patients with opioid use disorder from receiving appropriate treatment.
Essential oils have soared in popularity. Here is a primer to help you guide your patients in their safe use.
Federal officials said Thursday that Miami-Luken, an Ohio drug wholesale distributor, and two of its former executives have been charged for their roles in the U.S. opioid crisis.
In Texas, pharmacists can now be included in provider networks for all commercial health plans and be reimbursed for services they provide that are within their scope of practice.
U.S. drug overdose deaths last year dropped for the first time in nearly 2 decades, federal health officials reported Wednesday. According to CDC, the total number of fatal drug overdoses in the United States last year declined by about 5%.
Newly released data show that drug companies shipped billions of doses of oxycodone and hydrocodone across the United States as the nation's drug epidemic skyrocketed.
The pharmacy community suffered another disappointment at the hands of the Trump administration when a planned end to “safe harbor” protections under the federal anti-kickback statute for the rebates prescription drug manufacturers pay to PBMs was scuttled. The ambitious proposal reportedly could not withstand fears it would increase premiums for Medicare Part D beneficiaries—a frequent PBM talking point. Advocates for direct and indirect remuneration (DIR) reform were still reeling from May’s abandonment of a CMS Medicare rule requiring all price concessions to be assessed at point of sale.
Oklahoma's $17 billion lawsuit against Johnson & Johnson and its Janssen Pharmaceuticals subsidiary is now in the hands of Cleveland County District Judge Thad Balkman.